Clinical Trial Update: Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of zanubrutinib (BGB-3111) in relapsed or refractory mantle cell lymphoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: BeiGene | Conditions: Refractory Mantle Cell Lymphoma, Relapsed Mantle Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2020-05-13